Dr. William Williams reports

BRIACELL ADVANCES PERSONALIZED MELANOMA IMMUNOTHERAPY VACCINE CANDIDATE, BRIA-MEL+™

Briacell Therapeutics Corp.'s Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a key genetic engineering milestone, advancing the program toward clinical development.

• Cell-based immunotherapy program is designed to harness patients' own immune systems;
• Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing;
• Program builds on Briacell's experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform;
• Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in the United States in 2026.

Bria-MEL+ is a cell-based therapeutic cancer vaccine designed to harness a patient's own immune system to combat melanoma. The program is personalized yet "off the shelf": a simple patient saliva test will determine which of the several premanufactured treatment cell lines will be selected for personalized treatment, avoiding the need to manufacture a unique product for each individual patient.

"Bria-MEL+ is designed to combine the advantages of personalized immunotherapy with the accessibility of an off-the-shelf vaccine," said William V. Williams, MD, president and chief executive officer of Briacell. "By eliminating individualized manufacturing, we believe this approach has the potential to broaden access, shorten treatment timelines and reduce treatment costs while preserving patient-specific matching."

"Building on the encouraging efficacy and tolerability results from Briacell's metastatic breast cancer immunotherapy program, we continue to expand our pipeline with additional personalized, cell-based immunotherapy vaccine candidates, including Bria-MEL+ for melanoma," stated Miguel A. Lopez-Lago, PhD, Briacell's chief scientific officer.

About Bria-MEL+

Bria-MEL+ is a personalized, off-the-shelf, genetically modified whole-cell cancer vaccine designed to activate multiple components of the immune system, including innate and adaptive immune responses, to target and destroy melanoma cells. The program is derived from Briacell's Bria-OTS+ (off the shelf) cellular immunotherapy platform and is being developed using premanufactured cell lines selected through patient HLA matching.

Briacell's Bria-MEL+ expands the company's personalized immunotherapy platform which is led by Bria-IMT, currently in a pivotal phase 3 trial for metastatic breast cancer. Briacell is also advancing Bria-OTS in breast cancer, in which the first patient dosed experienced sustained complete resolution of a lung metastasis, and Bria-PROS+ in prostate cancer which has recently received Food and Drug Administration clearance to initiate clinical evaluation. The Bria-MEL+, Bria-PROS+ and Bria-OTS programs are based on matching patient HLA type with the corresponding immunotherapy cell line.

Earlier in 2026, Briacell reported preclinical data from the Bria-OTS+ platform at the AACR Annual Meeting, Bria-OTS+ demonstrated activation of both adaptive and innate immunity, including naive/resting T cells, dendritic cells and natural killer (NK) cells, inducing immune memory and eliciting "serial killer" activity against cancer cells. Briacell believes this multipronged immune activation supports the potential of the Bria-OTS+ platform to generate anti-tumour immune responses and informs the development of Bria-MEL+ for melanoma.

Briacell has commenced development activities to support production of Bria-MEL+ for potential clinical use. Bria-MEL+ recently passed a key milestone in the genetic engineering process, streamlining the path to the clinic.

Melanoma facts

The American Cancer Society estimates that approximately 112,000 new cases of melanomas will be diagnosed in the United States in 2026, including about 65,400 in men and 46,600 in women. Based on 2021 to 2023 Surveillance, Epidemiology and End Results (SEER) data, approximately 2.2 per cent of men and women will be diagnosed with skin melanoma during their lifetime.

Despite major advances in treatment, melanoma remains a significant unmet medical need. Approximately 8,510 people are expected to die from melanoma in the United States in 2026, including about 5,500 men and 3,010 women. Melanoma accounts for only about 1 per cent of skin cancers but causes a large majority of skin cancer deaths.

About Briacell Therapeutics Corp.

Briacell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.

We seek Safe Harbor.